Biotech News

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC)Oric Pharmaceuticals, Inc.Earnings

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collaboration and supply agreement with Bayer Provided updated rinzimetostat combination data in post-abiraterone mCRPC and in post-AR inhibitor mCRPC, consisting of

Related news

Oric Pharmaceuticals, Inc.

Oncology Resistance Biology ORIC Pharmaceuticals develops therapies intended to overcome mechanisms of treatment resistance in cancer. Its programs target epigenetic and signaling pathways that allow tumors to adapt to standard treatments. Rinzimetostat Rinzimetostat is an allosteric EED inhibitor that suppresses PRC2 activity. It is...

Recent company news

Stock data

Close
7.70 USD
Market cap
788.8M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States